This story was first published in digitalhealth.net

6,000 UK volunteers will be called upon to take part in a phase 3 trial for the coronavirus vaccine developed by The Janssen Pharmaceutical Companies of Johnson & Johnson.
This latest study, co-funded by the UK government’s Vaccine Taskforce which is being delivered by the NIHR, will recruit 30,000 people worldwide. It will test the safety and effectiveness of a new vaccine with two doses called ENSEMBLE 2.
Volunteers from a variety of age groups and backgrounds will begin taking part in the latest study at 17 National Institute for Health Research (NIHR) sites across the UK. These include Southampton, Bristol, Cardiff, London, Leicester, Sheffield, Manchester, Dundee and Belfast. Recruitment into the study will complete in March 2021 and the study will last for 12 months.
Dr. William van’t Hoff, CEO at the NIHR Clinical Research Network, said: “It is really great news to see the rapid development of vaccines like this one, achieving the phase 3 stage, when the vaccine is compared with a placebo to assess its effectiveness. Although we have heard last week of another effective vaccine, there is still much to be done before that might be used and, importantly, we must have a range of vaccines to tackle Covid-19. We are studying a range of vaccines that work in different ways and it is really important to test these in the UK. In particular, we want to offer the vaccine studies to more frontline workers, those over 65 as well as volunteers from Black, Asian and ethnic minority backgrounds. So I would urge people to consider signing up to the vaccine registry to be contacted about vaccine trials happening near them.”
The NHS Vaccine Registry was launched by the government in partnership with the NIHR, NHS Digital, the Scottish and Welsh governments and the Northern Ireland Executive in July. It aims to help create a database of people who consent to be contacted by the NHS to take part in clinical studies, to help speed up the development of a safe and effective vaccine.
This story was first published in digitalhealth.net
UK Building Regulations highlight toxic gas and smoke from layers of paint built up over multiple redecorations as a major cause of permanent ill health or death in a building fire.
Their concern rose with discovery the flame retardant paints most widely used paint along escape routes have been ones which to this day counter-productively use emission of heavy toxic gas to smother flames which rapidly spread along walls if layers of paint delaminate in a fire.
Northwich’s Victoria Infirmary (VIN) Community Diagnostic Centre (CDC) has enabled more patients
Adveco, the commercial hot water specialist, announces the launch of live metering of domestic ho
Sarah Greenslade, public affairs and communications officer at the British Parking Association looks at some of the problems and innovations in healthcare parking
It’s easy to assume that the comms team is there to handle press enquiries and the occasional social media storm – but the reality is that strategic communications can make a measurable impact across the entire organisation, from operational to financial, when done properly